Other Forms of Marrow Failure

Slide 1 · Other Forms of Marrow Failure

Mechanisms, morphology and clinicopathologic interpretation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes

Distinguish marrow replacement from diminished erythropoietin signaling.

Explain leukoerythroblastosis and teardrop erythrocytes mechanistically.

Relate renal, hepatic and endocrine disease to characteristic anemia patterns.

Use cause-specific clues to interpret complex underproduction anemia.

The lesion may involve marrow architecture, systemic support, or several mechanisms simultaneously.

Slide 3 · Four routes to inadequate erythropoiesis

Marrow replacement

Renal erythropoietin loss

Hepatocellular disease

Endocrine dysfunction

Distinct causal categories — not sequential stages

Different initiating lesions converge on diminished circulating red cells.

Only marrow replacement intrinsically requires space-occupying lesions.

Schematic

Slide 4 · Locate the dominant disturbance

Condition

Principal disturbance

Additional contribution

Myelophthisic anemia

Marrow space + architecture lost

Disordered cellular release

Chronic renal failure

Inadequate erythropoietin

Reduced RBC survival; bleeding

Hepatocellular disease

Impaired marrow function

Folate / iron deficits; membrane lipid change

Endocrine disease

Underproduction association

Often mild, normal RBC size and color

Slide 5 · Underproduction does not imply one mechanism

Stem-cell loss, restricted erythroid production and marrow displacement differ biologically.

Systemic disease can reduce erythropoiesis without a primary marrow infiltrate.

RBC survival, bleeding and nutritional deficiency may coexist with underproduction.

Do not infer the cause of low red-cell counts from “marrow failure” alone.

Slide 6 · Myelophthisic anemia: Defining lesion

Space-occupying processes replace normal marrow hematopoietic elements.

Replacement distorts the remaining hematopoietic environment.

Fibrosis and abnormal marrow egress help explain the blood-film phenotype.

The defining mechanism is structural displacement, not simply reduced erythropoietin.

Slide 7 · Malignancies associated with marrow replacement

Source

Pathologic role

Interpretive point

Breast carcinoma

Metastatic infiltration of marrow

A common metastatic primary

Lung carcinoma

Metastatic infiltration of marrow

Consider an epithelial malignancy

Prostate carcinoma

Metastatic infiltration of marrow

May replace hematopoietic space

Slide 8 · Marrow infiltration need not be malignant

Metastatic cancer

Most common myelophthisic cause

Often carcinomas of breast, lung or prostate

Infiltrating cells displace native hematopoiesis

Granulomatous disease

Non-neoplastic space-occupying process

Can distort marrow like a malignancy

Can produce the same downstream blood changes

A leukoerythroblastic pattern does not identify the precise infiltrating disease.

Slide 9 · Myeloproliferative neoplasms can end in marrow failure

The “spent phase” of a myeloproliferative neoplasm may produce myelophthisic anemia.

Progressive marrow fibrosis progressively displaces hematopoietic elements.

A late fibrotic state can resemble other causes of architectural replacement.

Consider a clonal marrow disorder even when no metastatic carcinoma is present.

Slide 10 · How infiltrative lesions produce anemia

Infiltrative lesion

→

Space occupied

→

Normal marrow displaced

→

Erythropoiesis compromised

Fibrosis can amplify the structural disturbance.

Both production capacity and marrow-to-blood release may be affected.

Schematic

Slide 11 · Two consequences of architectural distortion

Hematopoietic capacity

Normal marrow elements are displaced

Available space for red-cell production falls

Anemia reflects reduced effective output

Cellular traffic

Normal cellular egress is disturbed

Immature erythroid and myeloid forms escape

Abnormal red-cell shapes may appear

The blood film can provide evidence of marrow disturbance, not only RBC deficit.

Slide 12 · Fibrosis disrupts the marrow–blood interface

Distorted marrow

→

Altered cell egress

→

Early cell release

→

Leukoerythroblastosis

Fibrosis accompanies several myelophthisic processes.

The mechanism links a tissue-level lesion to a recognizable circulating-cell pattern.

Schematic

Slide 13 · Leukoerythroblastosis: A paired blood finding

Nucleated erythroid precursors circulate before normal maturation.

Immature granulocytic forms also enter the peripheral blood.

The coexistence of these populations signals disturbed marrow release.

The two immature cell lines together are more informative than anemia alone.

Slide 14 · Why nucleated erythroid cells appear

Normally organized marrow

Erythroid precursors mature within marrow compartments

Cell-release mechanisms preserve appropriate timing

Architecturally distorted marrow

Normal egress control is disturbed

Nucleated erythroid precursors enter circulation prematurely

Circulating nucleated erythroid cells are a consequence of altered release in this context.

Slide 15 · Why immature granulocytes appear

Normal marrow organization

Granulocytic maturation occurs before usual release

The marrow provides a regulated exit environment

Myelophthisic marrow

Infiltration and fibrosis disturb release

Immature granulocytic forms enter the blood

The same disordered architectural environment affects more than erythroid cells.

Slide 16 · Teardrop cells: Proposed deformation pathway

Fibrotic marrow

→

Tortuous escape

→

RBC deformation

→

Teardrop erythrocytes

Mechanical deformation during tortuous escape is the proposed explanation.

This finding is compatible with marrow distortion, but not specific to one cause.

Schematic

Slide 17 · Read the myelophthisic blood pattern as a whole

Finding

Direct observation

Interpretation

Anemia

Reduced circulating RBC compartment

Inadequate effective red-cell production

Nucleated erythroid cells

Early erythroid forms in blood

Disordered release

Immature granulocytes

Early myeloid forms in blood

Disordered release

Teardrop RBCs

Altered red-cell contours

Compatible with fibrotic distortion

Slide 18 · Conceptual map: Cells escaping a fibrotic marrow

MARROW: Distorted release

PERIPHERAL BLOOD: Findings

Nucleated erythroid precursors

→

Nucleated erythroid precursors

Immature granulocytic forms

→

Immature granulocytic forms

Teardrop erythrocytes

→

Teardrop erythrocytes

Schematic correspondence, not a blood-film image or a diagnostic cell drawing.

Slide 19 · Conceptual architecture: Preserved versus replaced marrow

Preserved hematopoietic space

Schematic

Space-occupying / fibrotic marrow

Infiltrating lesion

Schematic

Replacement and fibrosis reduce space and disturb regulated escape of immature cells.

Slide 20 · Architectural replacement is not classic aplasia

Myelophthisic process

Infiltration or fibrosis displaces marrow

Distorted cellular egress is characteristic

Leukoerythroblastic blood picture may occur

Aplastic anemia

Markedly hypocellular marrow with fat predominance

Stem-cell/progenitor failure is central

Reticulocytopenia and pancytopenia characterize disease

Both impair blood-cell production, but the underlying marrow lesion differs.

Slide 21 · Compare myelophthisis with pure red cell aplasia

Myelophthisic anemia

Space-occupying marrow disturbance

Immature erythroid and granulocytic cells may circulate

Broader architectural problem

Pure red cell aplasia

Selective suppression of erythroid progenitors

Severe cases show absent erythroid precursors

Other marrow lineages not intrinsically targeted

The lineage selectivity and marrow architecture help localize the lesion.

Slide 22 · What a suggestive smear can and cannot establish

Leukoerythroblastosis with teardrop forms supports marrow distortion.

Metastatic cancer, granulomatous infiltration and fibrotic myeloid disease remain possibilities.

The circulating pattern alone does not specify the underlying lesion.

Distinguish a mechanistic clue from a definitive etiologic diagnosis.

Slide 23 · Case: Anemia in a patient with carcinoma

A patient with a known solid-organ carcinoma develops anemia. The blood film contains nucleated erythroid precursors, immature granulocytic cells and teardrop erythrocytes.

Clinical information

Anemia in the setting of carcinoma

Leukoerythroblastic pattern

Teardrop-shaped erythrocytes

Which marrow process best unifies these findings?

Slide 24 · Case interpretation: Metastatic myelophthisis

The pattern is most consistent with architectural marrow distortion.

Metastatic carcinoma can occupy marrow space.

Secondary fibrosis and distorted egress permit premature cell release.

Teardrop erythrocytes support a fibrotic/distorted environment.

Myelophthisic anemia is the mechanistic diagnosis; The underlying lesion still requires confirmation.

Slide 25 · Case: Same smear, no known carcinoma

An anemic patient without a recognized malignancy has nucleated erythroid cells, immature granulocytes and teardrop red cells.

Clinical information

No established metastatic neoplasm

Marrow-distortion phenotype

Alternative infiltrative processes are plausible

What competing causal categories should remain open?

Slide 26 · Case interpretation: An etiologic differential

Do not equate a myelophthisic smear with metastatic cancer.

Metastatic carcinoma is common but not exclusive.

Granulomatous marrow involvement can produce identical downstream findings.

Advanced fibrotic myeloproliferative disease is another mechanism.

The smear identifies an architectural disturbance; Its cause must be established.

Slide 27 · Chronic renal failure: Anemia is expected

Anemia accompanies chronic renal failure across etiologies.

Severity tends to track the degree of uremia approximately.

Impaired erythropoietin synthesis is the dominant mechanistic driver.

Renal anemia is primarily failure of systemic erythroid support.

Slide 28 · Kidney-to-marrow erythropoietin axis

Renal EPO synthesis

→

Erythroid stimulation

→

Red-cell production

→

Circulating RBC mass

Damage to the kidney weakens this stimulatory axis.

Erythropoietin acts on committed erythroid progenitors in marrow.

Schematic

Slide 29 · The main lesion in renal anemia

Chronic kidney damage

→

Less erythropoietin

→

Inadequate erythropoiesis

→

Anemia

This remains the dominant mechanism across causes of chronic renal failure.

Reduced production is distinct from physical replacement of marrow.

Schematic

Slide 30 · Renal impairment and anemia severity

More pronounced uremia is generally associated with more severe anemia.

The relationship is approximate, not a diagnostic conversion formula.

Other contributions can change the observed severity in an individual.

Avoid treating renal function alone as a complete explanation of the hemoglobin level.

Slide 31 · Renal anemia is multifactorial

Component

Mechanistic change

Consequence

Dominant

Reduced renal erythropoietin synthesis

Insufficient red-cell production

Additional

Uremia shortens RBC lifespan

More rapid red-cell loss

Additional

Uremic platelet dysfunction

Bleeding can exacerbate anemia

Downstream

Blood loss and iron depletion

Reduced available iron for erythropoiesis

Slide 32 · Uremia can shorten red-cell survival

Uremic environment

→

Reduced RBC lifespan

→

Extravascular hemolysis

→

Additional anemia burden

The detailed mechanism of shortened survival remains uncertain.

The effect compounds the inadequate red-cell production caused by low EPO.

Schematic

Slide 33 · Uremic platelet dysfunction exacerbates anemia

Uremia

→

Impaired platelet function

→

Abnormal bleeding

→

Additional RBC loss

The source does not specify a single molecular cause of platelet dysfunction.

Bleeding provides a route from renal disease to further anemia.

Schematic

Slide 34 · Bleeding can secondarily restrict iron supply

Platelet dysfunction

→

Blood loss

→

Iron depletion

→

Constrained erythropoiesis

Iron deficiency can emerge as a downstream effect of chronic bleeding.

A correct explanation of renal anemia may therefore require more than EPO loss.

Schematic

Slide 35 · Renal anemia: Converging mechanisms

Deficient production

Kidney injury

↓

↓ Erythropoietin

↓

↓ Erythropoiesis

Shortened survival

Uremic milieu

↓

↓ RBC lifespan

↓

Extravascular hemolysis

Loss + iron restriction

Platelet dysfunction

↓

Bleeding

↓

Iron depletion

The dominant EPO pathway coexists with renal anemia modifiers.

Slide 36 · Separate low production from excess loss

Insufficient erythropoiesis

Damaged kidney synthesizes less erythropoietin

Erythroid progenitors receive inadequate support

Central mechanism

Additional red-cell deficit

Shorter circulating RBC survival

Uremic bleeding may occur

Possible subsequent iron deficiency

These components are complementary rather than mutually exclusive.

Slide 37 · Why recombinant erythropoietin helps

The missing kidney-derived growth signal is replaced pharmacologically.

Erythroid progenitors can receive renewed stimulatory input.

Recombinant erythropoietin can substantially improve renal anemia.

Treatment response is mechanistically consistent with erythropoietin deficiency.

Slide 38 · Why iron replacement also matters

Bleeding-associated iron deficiency may coexist with low erythropoietin.

Erythroid output requires an adequate substrate for hemoglobin synthesis.

Iron replacement can improve renal anemia when iron supply is insufficient.

Restoring a growth signal does not remove a concurrent iron deficit.

Slide 39 · Match an intervention to a causal defect

Observed pathway

Rationale

Mechanistic approach

Inadequate erythropoietin

Restore erythroid stimulus

Recombinant erythropoietin

Iron depletion from bleeding

Restore substrate for Hb synthesis

Iron replacement

Shortened RBC lifespan

Additional loss persists

Recognize as contributor

Uremic platelet dysfunction

Bleeding can continue

Recognize as contributor

Slide 40 · Marrow replacement versus renal underproduction

Myelophthisic anemia

Primary lesion occupies/distorts marrow

Leukoerythroblastosis and teardrops can appear

Egress architecture altered

Renal anemia

Primary lesion reduces EPO production

Shorter RBC lifespan and bleeding add to deficit

Marrow infiltration not required

Similar anemia may arise from very different anatomic and physiologic lesions.

Slide 41 · Case: Anemia with progressive uremia

A patient with chronic renal insufficiency develops worsening anemia and intermittent abnormal bleeding. There is no evidence supplied for an infiltrative marrow lesion.

Clinical information

Chronic kidney failure

Worsening uremia

Bleeding may be contributing

Which mechanism is dominant, and which additional pathway matters?

Slide 42 · Case interpretation: More than one renal mechanism

Start with inadequate erythropoietin production.

Renal damage suppresses the principal erythroid stimulus.

Uremia may shorten RBC survival.

Platelet dysfunction, bleeding and possible iron loss can compound the anemia.

Dominant EPO deficiency and secondary contributors should both appear in the explanation.

Slide 43 · Hepatocellular disease: Diverse causes, common anemia

Toxic, infectious and cirrhotic liver disease can be associated with anemia.

Reduced marrow function is a principal component of hepatic anemia.

Nutritional deficits, blood loss and altered RBC membranes may coexist.

A hepatic anemia often combines production and peripheral red-cell abnormalities.

Slide 44 · Different liver insults converge on anemia

Hepatic context

Shared consequence

Exacerbating mechanisms

Toxic hepatocellular disease

Depressed marrow function

Nutritional / bleeding factors

Infectious hepatocellular disease

Depressed marrow function

Nutritional / bleeding factors

Cirrhotic hepatocellular disease

Depressed marrow function

Nutritional / bleeding factors

Slide 45 · Hepatocellular injury and erythroid output

Hepatocellular disease

→

Depressed marrow function

→

Erythroid underproduction

→

Anemia

No single universal molecular mechanism explains the association.

Concurrent iron and folate deficiencies can exacerbate the result.

Schematic

Slide 46 · Lineage involvement in hepatic marrow suppression

Erythroid lineage

Preferentially affected

Anemia is the characteristic hematologic outcome

Leukocytes and platelets

Counts can also be depressed

These changes occur less often than the erythroid effect

Do not assume a uniform degree of pancytopenia in hepatic disease.

Slide 47 · Folate deficiency can intensify hepatic anemia

Poor nutrition

→

Reduced folate availability

→

Impaired erythroid DNA synthesis

→

Additional anemia

Folate deficiency is an important exacerbating factor.

The defective DNA-synthesis pathway is established elsewhere in this chapter.

Schematic

Slide 48 · Bleeding and iron deficiency in liver disease

Excessive bleeding

→

Loss of iron

→

Impaired Hb synthesis

→

Additional anemia

Poor nutritional status may independently restrict iron supply.

Iron deficiency is an aggravating factor rather than the only hepatic mechanism.

Schematic

Slide 49 · Hepatic lipid changes can enlarge red cells

Altered lipid milieu

→

Phospholipid + cholesterol gain

→

RBC membrane expansion

→

Slight macrocytosis

The change develops as RBCs circulate in peripheral blood.

This mechanism differs from folate/B12-related defective DNA replication.

Schematic

Slide 50 · Two pathways to increased RBC size

Liver-associated macrocytosis

RBCs acquire membrane lipid while circulating

Increased membrane area can enlarge cells

Often slight macrocytosis

Megaloblastic macrocytosis

Folate/B12 deficiency impairs DNA replication

Abnormal enlarged erythroid precursors develop

Ineffective hematopoiesis may follow

A shared MCV pattern does not imply an identical cellular mechanism.

Slide 51 · Why the blood picture can be heterogeneous

Decreased erythroid production provides one component of anemia.

Nutritional folate and iron deficits may be superimposed.

Membrane-lipid changes can shift measured RBC size upward.

Leukocyte or platelet reductions may occur but are less frequent.

Avoid forcing hepatic anemia into a single uniform morphology.

Slide 52 · Renal versus hepatic anemia

Chronic renal failure

Dominant EPO deficiency

Uremic shortened RBC survival / bleeding

Iron deficiency may develop

Hepatocellular disease

Depressed marrow function with multifactorial additions

Folate and iron deficiency common aggravators

Membrane lipid effects cause slight macrocytosis

The causal priorities differ even when systemic organ failure is present.

Slide 53 · Case: Macrocytosis in hepatocellular disease

A patient with longstanding cirrhotic liver disease develops mild macrocytosis and anemia. The history also suggests poor nutrition and recurrent bleeding.

Clinical information

Cirrhosis

Slight macrocytosis

Possible folate and iron deficits

Name the distinct pathways that can coexist without assuming one mechanism.

Slide 54 · Case interpretation: Layered hepatic mechanisms

Separate the red-cell size change from additional production deficits.

Lipid-related membrane acquisition may cause slight macrocytosis.

Reduced marrow function contributes to anemia.

Folate deficiency and iron loss can exacerbate impaired production.

A single morphological descriptor does not resolve the full etiology.

Slide 55 · Endocrine disorders: A separate underproduction group

Endocrine dysfunction can contribute to diminished erythropoiesis.

Hypothyroidism is specifically highlighted.

The associated anemia is typically mild, normocytic and normochromic.

This presentation is a pattern association, not a disease-specific hematologic test.

Slide 56 · Why normal cell size does not exclude anemia

Cell quantity

Red-cell production can be reduced

The circulating red-cell compartment may decline

Cell morphology

RBC size may remain normal

Hemoglobin coloration may remain normal

A mild normocytic, normochromic anemia can still reflect systemic endocrine dysfunction.

Slide 57 · Diagnostic specificity of the RBC-size pattern

Pattern

Representative setting

Interpretive limit

Normocytic / normochromic

Hypothyroidism-associated anemia

Not disease-specific

Slightly macrocytic

Hepatocellular disease

Membrane lipid change may contribute

Leukoerythroblastic / teardrops

Myelophthisic marrow

Suggests distorted egress

Low red-cell production

Renal EPO deficiency

Requires clinical renal context

Slide 58 · Four causes: Mechanism and distinguishing context

Cause

Dominant issue

Helpful clue

Marrow infiltration

Displacement + fibrosis

Leukoerythroblastosis, teardrops

Chronic renal failure

Reduced erythropoietin

Uremia; possible bleeding/iron loss

Hepatocellular disease

Reduced marrow function + other effects

Slight macrocytosis; nutritional overlap

Hypothyroidism

Endocrine-associated underproduction

Usually mild normocytic/normochromic anemia

Slide 59 · Which marrow lineage is emphasized?

Mechanism

Erythroid effect

Other blood-cell effects

Marrow replacement

Hematopoietic space displaced

Immature erythroid and granulocytic release

Pure red cell aplasia

Selective erythroid progenitor suppression

Other lineages relatively spared

Aplastic anemia

General marrow production failure

Pancytopenia

Hepatocellular disease

Preferential erythroid depression

WBC / platelets less often depressed

Slide 60 · Peripheral morphology must be interpreted causally

Teardrop red cells plus immature forms point toward marrow distortion.

Slight macrocytosis in hepatic failure may arise from altered membrane lipids.

Normocytic morphology does not exclude an endocrine contribution.

Red-cell morphology cannot alone settle all four etiologies.

Link a blood finding to its mechanism, then evaluate the clinical context.

Slide 61 · Mechanism-first interpretation of underproduction anemia

Underproduction anemia: Interpret the mechanism

Marrow architecture

Immature forms + teardrops

Renal endocrine support

Kidney failure / low EPO mechanism

Hepatic pathways

Membrane lipid + nutrition

Endocrine setting

Hypothyroidism; Mild normocytic

Look for more than one pathway in systemic disease

Interpretive teaching algorithm, not a validated diagnostic rule.

Slide 62 · Avoid three common reasoning errors

Do not identify every leukoerythroblastic smear as metastatic carcinoma.

Do not explain renal anemia solely by erythropoietin loss when bleeding may coexist.

Do not call all macrocytosis “megaloblastic” in patients with liver disease.

The distinguishing feature is mechanism, not a single surface finding.

Slide 63 · Integrated case: Renal and hepatic disease coexist

A patient with chronic kidney disease and cirrhotic hepatocellular disease develops anemia, slight macrocytosis and recurrent bleeding.

Clinical information

Potential deficiency of EPO

Hepatic lipid and marrow effects

Bleeding-associated iron depletion

Would a single-pathway explanation be defensible?

Slide 64 · Integrated case: Construct a causal explanation

A combined explanation is more coherent than exclusive attribution.

Renal disease reduces EPO-driven red-cell production.

Hepatic disease may depress marrow function and enlarge RBC membranes.

Bleeding and possible iron deficiency add another mechanism.

Do not equate a plausible dominant cause with the only cause.

Slide 65 · Clinical pattern recognition: Four short prompts

Presentation

Mechanism most directly suggested

Anemia, teardrops and nucleated erythroid cells

Myelophthisic marrow distortion

Uremia with inadequate erythropoiesis

Reduced renal erythropoietin

Hepatocellular disease and slight macrocytosis

Lipid-associated membrane enlargement

Hypothyroidism and mild normocytic anemia

Endocrine-associated underproduction

Slide 66 · Final synthesis: Local lesion or systemic support?

Marrow architecture

EPO support

Hepatic milieu

Endocrine milieu

Distinct causal categories — not sequential stages

All four categories can culminate in inadequate effective red-cell production.

Search for concurrent RBC survival, bleeding or nutritional contributors.

Schematic

Slide 67 · Principal conclusions

Myelophthisis: Marrow infiltration/fibrosis produces displacement and disturbed cell release.

Renal failure: Decreased EPO dominates; Uremia, bleeding and iron loss add effects.

Hepatic disease: Preferential erythroid impairment plus nutritional and membrane-lipid effects.

Endocrine disease: Hypothyroidism can cause mild normocytic, normochromic anemia.

Mechanism + morphology + organ context produces a stronger interpretation than MCV alone.

Slide 68 · Principal reference

Robbins, Cotran & Kumar

Pathologic Basis of Disease, 11th edition (2026)

Chapter 14: Red Blood Cell and Bleeding Disorders

Related marrow fibrosis context: Chapter 13

Primary section: “Other Forms of Marrow Failure”